FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan

Phase 3 Active not recruiting 54 enrolled kewen Chen,MD

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn if Finerenone works to treat proteinuria patients after kidney transplantation. It will also learn about the safety of Finerenone. The main questions it aims to answer are: Does Finerenone lower the number of UACR values in kidney transplant recipients?? What medical problems do participants have when taking Finerenone? Researchers will compare Finerenone to Dapagliflozin to see if Finerenone works to treat proteinuria patients after kidney transplantation.

Timeline

Start: 2025-01-30
Primary completion: 2027-10-01
Completion: 2028-03-31

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	10 mg	Oral
Subject	Dapagliflozin	Small molecule	20 mg	Oral
Subject	Finerenone	Small molecule	10 mg	Oral
Subject	Finerenone	Small molecule	20 mg	Oral
Background	Valsartan	Small molecule	80 mg	Oral
Background	Valsartan	Small molecule	150 mg	Oral

FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan

Summary

Timeline

Publications

Drugs

Indications